Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Differences in Cancer Survival with Relative versus Cause-Specific Approaches: An Update Using More Accurate Life Tables.

Forjaz de Lacerda G, Howlader N, Mariotto AB.

Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1544-1551. doi: 10.1158/1055-9965.EPI-19-0125. Epub 2019 Jun 20.

PMID:
31221717
2.

Cancer treatment and survivorship statistics, 2019.

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL.

CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.

3.

Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer.

Mariotto AB, Zou Z, Zhang F, Howlader N, Kurian AW, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1332-1341. doi: 10.1158/1055-9965.EPI-17-1129. Epub 2018 Oct 18.

PMID:
30337342
4.

Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival.

Mariotto AB, Zou Z, Johnson CJ, Scoppa S, Weir HK, Huang B.

PLoS One. 2018 Jul 25;13(7):e0201034. doi: 10.1371/journal.pone.0201034. eCollection 2018.

5.

Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions.

Forjaz de Lacerda G, Kelly SP, Bastos J, Castro C, Mayer A, Mariotto AB, Anderson WF.

Cancer Epidemiol. 2018 Jun;54:12-18. doi: 10.1016/j.canep.2018.03.003. Epub 2018 Mar 13.

6.

New Opportunities for Cancer Health Services Research: Linking the SEER-Medicare Data to the Nursing Home Minimum Data Set.

Thomas KS, Boyd E, Mariotto AB, Penn DC, Barrett MJ, Warren JL.

Med Care. 2018 Dec;56(12):e90-e96. doi: 10.1097/MLR.0000000000000877.

PMID:
29401187
7.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

8.

The history and use of cancer registry data by public health cancer control programs in the United States.

White MC, Babcock F, Hayes NS, Mariotto AB, Wong FL, Kohler BA, Weir HK.

Cancer. 2017 Dec 15;123 Suppl 24:4969-4976. doi: 10.1002/cncr.30905.

9.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

10.

Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States.

Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-815. doi: 10.1158/1055-9965.EPI-16-0889. Epub 2017 May 18.

11.

Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.

Howlader N, Mariotto AB, Besson C, Suneja G, Robien K, Younes N, Engels EA.

Cancer. 2017 Sep 1;123(17):3326-3334. doi: 10.1002/cncr.30739. Epub 2017 May 2.

12.

Is prostate cancer different in black men? Answers from 3 natural history models.

Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R.

Cancer. 2017 Jun 15;123(12):2312-2319. doi: 10.1002/cncr.30687. Epub 2017 Apr 24.

13.

Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011).

Bradley CJ, Yabroff KR, Mariotto AB, Zeruto C, Tran Q, Warren JL.

J Clin Oncol. 2017 Feb 10;35(5):529-535. doi: 10.1200/JCO.2016.69.4166. Epub 2017 Jan 3.

14.

Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States.

Howlader N, Shiels MS, Mariotto AB, Engels EA.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1289-96. doi: 10.1158/1055-9965.EPI-16-0273. Epub 2016 Jul 14.

15.

Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States.

Bluethmann SM, Mariotto AB, Rowland JH.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36. doi: 10.1158/1055-9965.EPI-16-0133.

16.

Cancer treatment and survivorship statistics, 2016.

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A.

CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.

17.

Erratum. Cancer Survival: An Overview of Measures, Uses, and Interpretation.

Mariotto AB.

J Natl Cancer Inst Monogr. 2015 May;2015(51):97. doi: 10.1093/jncimonographs/lgv001. No abstract available.

PMID:
26063897
18.

Survivors of childhood cancer in the United States: prevalence and burden of morbidity.

Phillips SM, Padgett LS, Leisenring WM, Stratton KK, Bishop K, Krull KR, Alfano CM, Gibson TM, de Moor JS, Hartigan DB, Armstrong GT, Robison LL, Rowland JH, Oeffinger KC, Mariotto AB.

Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):653-63. doi: 10.1158/1055-9965.EPI-14-1418.

19.

Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death.

Howlader N, Mariotto AB, Woloshin S, Schwartz LM.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):255-64. doi: 10.1093/jncimonographs/lgu022.

20.

Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer.

Stedman MR, Feuer EJ, Mariotto AB.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):244-54. doi: 10.1093/jncimonographs/lgu015.

21.

The impact of state-specific life tables on relative survival.

Stroup AM, Cho H, Scoppa SM, Weir HK, Mariotto AB.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):218-27. doi: 10.1093/jncimonographs/lgu017.

22.

Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies.

Weir HK, Johnson CJ, Mariotto AB, Turner D, Wilson RJ, Nishri D, Ward KC.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):198-209. doi: 10.1093/jncimonographs/lgu018.

23.

When do changes in cancer survival mean progress? The insight from population incidence and mortality.

Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):187-97. doi: 10.1093/jncimonographs/lgu014.

24.

Cancer survival: an overview of measures, uses, and interpretation.

Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, Woloshin S, Schwartz LM.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):145-86. doi: 10.1093/jncimonographs/lgu024. Erratum in: J Natl Cancer Inst Monogr. 2015 May;2015(51):97.

25.

Expected population impacts of discontinued prostate-specific antigen screening.

Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR.

Cancer. 2014 Nov 15;120(22):3519-26. doi: 10.1002/cncr.28932. Epub 2014 Jul 25.

26.

Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS.

Ann Intern Med. 2014 Jul 15;161(2):104-12. doi: 10.7326/M13-2867.

27.

Cancer treatment and survivorship statistics, 2014.

DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A.

CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71. doi: 10.3322/caac.21235. Epub 2014 Jun 1. Review.

28.

Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Eheman CR, Ward EM.

Cancer. 2014 May 1;120(9):1290-314. doi: 10.1002/cncr.28509. Epub 2013 Dec 16.

29.

Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies.

Cho H, Klabunde CN, Yabroff KR, Wang Z, Meekins A, Lansdorp-Vogelaar I, Mariotto AB.

Ann Intern Med. 2013 Nov 19;159(10):667-76. doi: 10.7326/0003-4819-159-10-201311190-00005.

PMID:
24247672
30.

Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients.

Mariotto AB, Wang Z, Klabunde CN, Cho H, Das B, Feuer EJ.

J Clin Epidemiol. 2013 Dec;66(12):1376-85. doi: 10.1016/j.jclinepi.2013.07.002. Epub 2013 Sep 10.

31.

Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence.

Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ.

Am J Epidemiol. 2013 Aug 1;178(3):339-49. doi: 10.1093/aje/kws580. Epub 2013 Jul 3.

32.

Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care.

de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70. doi: 10.1158/1055-9965.EPI-12-1356. Epub 2013 Mar 27.

33.

The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.

Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB.

Cancer. 2012 Dec 1;118(23):5955-63. doi: 10.1002/cncr.27594. Epub 2012 May 17.

34.

The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients.

Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, Schrag D, Hankey BF.

Cancer. 2012 Nov 15;118(22):5652-62. doi: 10.1002/cncr.27615. Epub 2012 May 8. Erratum in: Cancer. 2013 Apr 15;119(8):1602-4.

35.

The impact of PLCO control arm contamination on perceived PSA screening efficacy.

Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R.

Cancer Causes Control. 2012 Jun;23(6):827-35. doi: 10.1007/s10552-012-9951-8. Epub 2012 Apr 10.

36.

Development of a prognostic model for six-month mortality in older adults with declining health.

Han PK, Lee M, Reeve BB, Mariotto AB, Wang Z, Hays RD, Yabroff KR, Topor M, Feuer EJ.

J Pain Symptom Manage. 2012 Mar;43(3):527-39. doi: 10.1016/j.jpainsymman.2011.04.015. Epub 2011 Nov 8.

37.

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.

Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R.

J Clin Epidemiol. 2011 Dec;64(12):1412-7. doi: 10.1016/j.jclinepi.2011.06.011.

38.

Cancer survivors: a booming population.

Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):1996-2005. doi: 10.1158/1055-9965.EPI-11-0729.

39.

Projections of the cost of cancer care in the United States: 2010-2020.

Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML.

J Natl Cancer Inst. 2011 Jan 19;103(2):117-28. doi: 10.1093/jnci/djq495. Epub 2011 Jan 12. Erratum in: J Natl Cancer Inst. 2011 Apr 20;103(8):699.

40.

Improved estimates of cancer-specific survival rates from population-based data.

Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA.

J Natl Cancer Inst. 2010 Oct 20;102(20):1584-98. doi: 10.1093/jnci/djq366. Epub 2010 Oct 11.

41.

Population-based survival-cure analysis of ER-negative breast cancer.

Huang L, Johnson KA, Mariotto AB, Dignam JJ, Feuer EJ.

Breast Cancer Res Treat. 2010 Aug;123(1):257-64. doi: 10.1007/s10549-010-0752-z. Epub 2010 Feb 4.

PMID:
20130982
42.

Adverse events after outpatient colonoscopy in the Medicare population.

Warren JL, Klabunde CN, Mariotto AB, Meekins A, Topor M, Brown ML, Ransohoff DF.

Ann Intern Med. 2009 Jun 16;150(12):849-57, W152.

PMID:
19528563
43.

Long-term survivors of childhood cancers in the United States.

Mariotto AB, Rowland JH, Yabroff KR, Scoppa S, Hachey M, Ries L, Feuer EJ.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1033-40. doi: 10.1158/1055-9965.EPI-08-0988. Epub 2009 Mar 31.

44.

Breast cancer survivors in the United States: geographic variability and time trends, 2005-2015.

De Angelis R, Tavilla A, Verdecchia A, Scoppa S, Hachey M, Feuer EJ, Mariotto AB.

Cancer. 2009 May 1;115(9):1954-66. doi: 10.1002/cncr.24217.

45.

Estimates and projections of value of life lost from cancer deaths in the United States.

Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ.

J Natl Cancer Inst. 2008 Dec 17;100(24):1755-62. doi: 10.1093/jnci/djn383. Epub 2008 Dec 9.

46.

Current and future utilization of services from medical oncologists.

Warren JL, Mariotto AB, Meekins A, Topor M, Brown ML.

J Clin Oncol. 2008 Jul 1;26(19):3242-7. doi: 10.1200/JCO.2007.14.6357.

PMID:
18591559
47.

Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?

Huang L, Cronin KA, Johnson KA, Mariotto AB, Feuer EJ.

Cancer. 2008 May 15;112(10):2289-300. doi: 10.1002/cncr.23425.

48.

Projections of the costs associated with colorectal cancer care in the United States, 2000-2020.

Yabroff KR, Mariotto AB, Feuer E, Brown ML.

Health Econ. 2008 Aug;17(8):947-59.

PMID:
17910108
49.
50.

Multiple cancer prevalence: a growing challenge in long-term survivorship.

Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ.

Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):566-71.

Supplemental Content

Loading ...
Support Center